We are live on ! Find out more
GTBP icon

GT Biopharma
GTBP

34 hedge funds and large institutions have $4.36M invested in GT Biopharma in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.07% less ownership

Funds ownership: 0.34% → 0.27% (-0.07%)

28% less funds holding

Funds holding: 47 → 34 (-13)

46% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 13

53% less capital invested

Capital invested by funds: $9.28M → $4.36M (-$4.92M)

87% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 15

Holders
34
Holders Change
-13
Holders Change %
-27.66%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
7
Reduced
13
Closed
15
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$83.4K
2
VF
Virtu Financial
New York
+$63.4K
3
CLOS
Compagnie Lombard Odier SCmA
Switzerland
+$51K
4
Goldman Sachs
Goldman Sachs
New York
+$36.6K
5
State Street
State Street
Massachusetts
+$22.2K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$333K
2
E
Ergoteles
New York
-$242K
3
Millennium Management
Millennium Management
New York
-$230K
4
Renaissance Technologies
Renaissance Technologies
New York
-$193K
5
Citadel Advisors
Citadel Advisors
Florida
-$182K
Name Holding Trade Value Shares
Change 		Change in
Stake
Simplex Trading
26
Simplex Trading
Illinois
$1K -$2.37K -31 -48%
Wells Fargo
27
Wells Fargo
California
$1K -$153 -2 -10%
BBPWM
28
Blue Bell Private Wealth Management
Pennsylvania
$1K – – –
Osaic Holdings
29
Osaic Holdings
Arizona
$1K – – –
TF
30
TimeScale Financial
Massachusetts
$1K – – –
APA
31
American Portfolios Advisors
New York
$25 – – –
E
32
Ergoteles
New York
– -$242K -2,703 Closed
Renaissance Technologies
33
Renaissance Technologies
New York
– -$193K -2,157 Closed
Citadel Advisors
34
Citadel Advisors
Florida
– -$182K -2,033 Closed
Susquehanna International Group
35
Susquehanna International Group
Pennsylvania
– -$133K -1,484 Closed
Bank of America
36
Bank of America
North Carolina
– -$124K -1,376 Closed
GCS
37
Gordian Capital (Singapore)
Singapore
– -$103K -1,167 Closed
CA
38
Crumly & Associates
Illinois
– -$96K -1,072 Closed
Charles Schwab
39
Charles Schwab
California
– -$78K -862 Closed
Franklin Resources
40
Franklin Resources
California
– -$57K -640 Closed
Group One Trading
41
Group One Trading
Illinois
– -$44.3K -579 -99%
Two Sigma Advisers
42
Two Sigma Advisers
New York
– -$30K -340 Closed
Russell Investments Group
43
Russell Investments Group
United Kingdom
– -$21K -241 Closed
Citigroup
44
Citigroup
New York
– -$1K -6 Closed
1
2

GTBP Hedge Fund Activity: Q3 2022 in Review

34 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q3 2022, worth a combined $4.36M — down 53% from $9.28M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of GTBP and 2 opened new positions — a net loss of 13 holders — while 13 trimmed existing stakes and 7 added.

The largest buyer was Jane Street, opening a new position worth an estimated $83.4K. The largest seller was Morgan Stanley, cutting an estimated $333K.

  • 34 institutional investors held GT Biopharma (GTBP) as of Q3 2022, down from 47 in Q2 2022.
  • Funds reported $4.36M of GT Biopharma stock for Q3 2022, down 53% quarter-over-quarter.
  • 2 funds opened new GT Biopharma positions in Q3 2022 and 15 closed out, a net change of -13 holders.
  • The largest GT Biopharma buyer in Q3 2022 was Jane Street, an estimated $83.4K added.
  • The largest GT Biopharma seller in Q3 2022 was Morgan Stanley, an estimated $333K sold.

Based on aggregated 13F filings for Q3 2022.